IKT Earnings Date: Nov 13, 2026 (Estimated) — Inhibikase Therapeutics, Inc.
NASDAQ
Updated
When is IKT's next earnings date?
Inhibikase Therapeutics, Inc. (IKT) is expected to report Q3 2026 earnings on Friday, November 13, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.11 on revenue of $187,500.
How did IKT do in its last earnings report?
In its most recent report on Aug 11, 2026 (Q2 2026), Inhibikase Therapeutics, Inc. posted EPS of -$0.11 versus the -$0.11 estimate, a miss of 22.2%. Revenue was $0. The stock's 1-day post-earnings move was -2.0%.
How much does IKT stock move after earnings?
IKT beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 3.9% (up or down) in the day after earnings.
About Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-11 | Q2 2026 | -0.11 | -0.11 | -22.22% | $0 | ❌ Miss | -2.04% | -2.04% | -4.90% |
| 2026-05-12 | Q1 2026 | -0.10 | -0.10 | +0.00% | $0 | ➖ Inline | -1.04% | -18.23% | -13.02% |
| 2025-11-14 | Q3 2025 | -0.12 | -0.13 | -8.33% | $0 | ❌ Miss | -0.65% | -2.61% | +4.58% |
| 2025-08-14 | Q2 2025 | -0.09 | -0.11 | -22.22% | $0 | ❌ Miss | +2.34% | -1.75% | -6.43% |
| 2024-11-14 | Q3 2024 | -0.67 | -0.65 | +2.99% | $0 | ✅ Beat | -2.48% | -18.18% | +42.15% |
| 2024-08-14 | Q2 2024 | -0.67 | -0.66 | +1.49% | $0 | ✅ Beat | -5.38% | +11.54% | -9.23% |
| 2024-05-15 | Q1 2024 | -0.79 | -0.73 | +7.59% | $0 | ✅ Beat | -11.56% | -5.03% | -29.15% |
| 2024-03-27 | Q4 2023 | -0.85 | -0.64 | +24.71% | $1,000 | ✅ Beat | -6.09% | -4.35% | -25.65% |
Showing last 8 quarters.